• Bi02 Medical

  Led · Series B · Mar 2012

  Bio2 Medical is a Golden, CO-based developer of a catheter to protect critically ill patients from acute pulmonary embolism (PE). The company introduced the Angel® Catheter, an IVC filter that received FDA clearance for a prophylactic use indication. It recently closed a $3M second tranche of venture debt financing provided by Oxford Finance. The company intends to use the funds to further execute its U.S. commercialization plan for the Angel® Catheter, including hiring a sales team, building inventory and executing market development initiatives. Led by Chairman and Chief Executive Officer Christopher E. Banas, Bio2 Medical has to date raised $43.1M of institutional funding. BiO2 Medical develops the Angel® Catheter, a mechanical pulmonary embolism protection device with a prophylactic indication whose clinical trials were successfully completed. The catheter is designed as a femoral approach central venous catheter (CVC) that enables bedside venous access without the need for fluoroscopy and provides immediate pulmonary embolism protection through a permanently attached, 100% retrievable inferior vena cava (IVC) filter. The company is led by Chairman and CEO Christopher E. Banas. BiO2 intends to use new financing to support its US product launch, expand its US and OUS sales force, fund incremental R&D projects, and develop general infrastructure. The company is based in San Antonio, Texas and Golden, Colorado. Current operating metrics such as revenue or user numbers were not disclosed in the article. BiO2 Medical develops the Angel Catheter, an implantable device intended to prevent pulmonary embolisms in hospitalized patients at high risk, particularly those with severe head and spinal injuries for whom anticoagulants can be dangerous. The device is indicated for up to 30 days of use and holds a CE mark for sale in Europe; it remains investigational in the U.S. and is not FDA‑cleared. The company is conducting a 150‑patient, multicenter trial to evaluate the device’s efficacy. A regulatory filing shows BiO2 has raised $4 million so far as part of a $10 million round. The filing indicates the $4 million was provided by a single investor and does not specify the instrument type. BiO2 has raised more than $35 million since its founding in 2006 and is based in Texas. BiO2 Medical is a San Antonio, Texas–based medical device manufacturer developing the Angel™ Catheter, a combined central venous catheter and inferior vena cava (IVC) filter. The Angel Catheter is intended to protect critically ill patients from potentially fatal pulmonary embolism (PE). The company intends to use new funding to commercialize the Angel Catheter. BiO2 has R&D and manufacturing operations in Golden, Colorado. It is led by Chairman and CEO Christopher E. Banas and Chief Medical Officer Dr. Luis F. Angel. The company raised $12M in a Series C round to support these commercialization efforts. BiO2 Medical is a San Antonio, Texas–based medical device manufacturer developing the Angel™ Catheter, a combined central venous catheter and inferior vena cava (IVC) filter intended to protect critically ill patients from potentially fatal pulmonary embolism (PE). The company is led by Chairman and CEO Christopher E. Banas and Chief Medical Officer Dr. Luis F. Angel. BiO2 has corporate offices and R&D and manufacturing operations in Golden, Colorado. The Angel Catheter is positioned as a dual-function device combining central venous access with IVC filtration. The recent financing has supported completion of Design Verification Testing in support of a CE Mark submission, initiation of a first-in-human clinical study in Medellin, Colombia, and a Pre-IDE meeting with the FDA. Financially, BiO2 completed a $13.7M Series B round which included conversion of a $1.0M State of Texas Emerging Technology Fund award.

No current team members are available.